Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2025 Nov 12;5(11):e0004499. doi: 10.1371/journal.pgph.0004499

Trust in healthcare providers, information sources, and concerns for new maternal vaccines among pregnant and lactating women in Kenya

Jessica L Schue 1, Berhaun Fesshaye 1, Emily Miller 1, Prachi Singh 1, Molly Sauer 1, Rosemary Njogu 2, Rose Jalang’o 3, Joyce Nyiro 4, Ruth A Karron 5, Rupali J Limaye 1,6,*
Editor: Claire E von Mollendorf7
PMCID: PMC12611154  PMID: 41223190

Abstract

New maternal vaccines have the potential to reduce morbidity and mortality for infants from common illnesses that pose the greatest risk in the earliest phase of their life. Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections among infants under six months of age. With the recent approval of a maternal vaccine for RSV, this study aimed to understand decision-making factors among pregnant and lactating women for receiving a newly licensed vaccine during pregnancy. Pregnant and lactating women from two counties in Kenya, Nakuru and Mombasa, were recruited to complete a cross-sectional survey in July-September 2022. The survey explored topics of trust in various types of sources for information about new maternal vaccines, the importance of a healthcare provider’s recommendation of a new maternal vaccine, and concerns about new maternal vaccines. We surveyed 400 pregnant and lactating women. In both counties, information about the new vaccine was most trusted when coming from healthcare providers, and least trusted when coming from social media. Women’s intention to receive a new maternal vaccine was heavily influenced by a positive recommendation from a healthcare provider. The greatest concerns about a new vaccine were side effects and the vaccine’s ingredients. The information and recommendation from a healthcare provider are important influences on decision-making for new maternal vaccines. As a new maternal immunization for RSV becomes more available, healthcare providers should be engaged early to reduce vaccine hesitancy amongst providers and equip providers with appropriate information tailored to pregnant women about the RSV maternal vaccine.

Introduction

Maternal immunization, or immunization during pregnancy, allows the pregnant person to pass antibodies through the placenta to the fetus, thereby providing passive immunity that protects infants at birth and in the first weeks and months of life [1]. Vaccination during pregnancy can also serve to protect the pregnant person from experiencing severe disease or death themselves, and maternal infections are themselves a contributor to preterm birth which can subsequently contribute to neonatal mortality [2,3].

The first vaccine to be administered during pregnancy was tetanus toxoid to prevent neonatal tetanus [4]. Since then, tetanus-diphtheria (Td) or tetanus-diphtheria-pertussis (Tdap) and SARS-CoV2/COVID-19 vaccines have been added to the list of maternal immunizations that are now commonly implemented worldwide [4]. In high- and middle-income countries, influenza and, most recently, respiratory syncytial virus (RSV) vaccines are recommended for pregnant women, whereas these vaccines are not standard in low- and middle-income countries [5,6]. Looking ahead, several maternal Group B Streptococcus (GBS) vaccine candidates are currently in development to help overcome the limitations of existing prevention strategies and better protect newborns from infection [7], and maternal immunization against malaria and tuberculosis is also being considered.

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children under five, and in 2019, was estimated to cause more than 33 million infections, 3.6 million hospital admissions, and more than 100,000 deaths [8]. Low- and middle-income countries (LMICs) bear a disproportionate burden of the disease, accounting for 95% of infections and 97% of deaths [8]. Additionally, RSV disease is most severe when children are entering their first RSV season, and preterm infants are disproportionately affected, making up 25% of RSV hospitalization burden in 2019 [1,9].

A bivalent RSVpreF maternal vaccine has been approved for use and recommended to pregnant women in more than 40 high- and middle-income countries as of the end of 2024, with the World Health Organization recommending that all countries introduce either the maternal vaccine or a long-acting monoclonal antibody to protect infants against RSV disease [10,11]. Unlike maternal RSV vaccines, long-acting RSV monoclonal antibodies are administered to infants to provide protection for several months, but are costly with extremely limited supply, leaving them out of reach in all but higher-income settings [12,13]. Given the limited availability of RSV monoclonal antibodies in LMICs, the maternal RSV vaccine is particularly important. The RSV maternal vaccine is recommended for use during the third trimester of pregnancy, with recommendations for the exact gestational age windows varying by country [10,14].

Previous research in Kenya has shown a substantial burden of RSV-related illness and death among children under 5 years of age, with highest levels of morbidity and mortality occurring in the first 6 months of life [15]. Additionally, research on seasonality has found that maximum temperature, absolute humidity, and weekly number of births are drivers of annual RSV epidemics in Kenya [16]. While non-medically attended RSV disease accounts for most of the country’s burden, RSV hospitalization is also a significant cause of economic burden for households in Kenya [17,18]. This makes preventative care like vaccination in pregnancy especially important as it can not only decrease RSV-related morbidity and mortality, but also decrease economic burden in Kenya. There has been limited prior research done specifically with pregnant women in Kenya on demand generation and information sources for a maternal RSV vaccine. One study of pregnant and lactating women and their community members found that healthcare workers were trusted advisors and information sources, as were family and community members and traditional media [19]. Other studies with pregnant and lactating women and Kenyan healthcare workers found that most of the participants were not aware of RSV disease or maternal vaccines and recommended the creation of RSV awareness education materials [20,21]. Additionally, a systematic review that included studies conducted in Kenya found that attitudes toward RSV prevention products were relatively positive despite low knowledge of RSV disease, similarly emphasizing the importance of education on RSV disease and prevention products for all target audiences, includingpregnant women, healthcare providers, and policymakers [22].

Given that a maternal RSV vaccine may be available in Kenya in the next few years and the importance of effectively educating and communicating about this vaccine, this study aims to describe which information sources pregnant women trusted, their attitudes toward vaccines in pregnancy, and their intentions to vaccinate as future maternal vaccines become available.

Methods

The target population of this study was pregnant and lactating women in both rural and urban settings of Kenya. To this end, participants were recruited from 20 health facilities in Nakuru County (rural) and Mombasa County (urban); these counties were identified in consultation with Ministry of Health officials and in-country partners to balance population and geographic diversity with accessibility and feasibility for data collection. A range of health facility types was included to improve the representativeness of the sample, from level 2 (community clinics) through level 5 (specialized referral hospitals). We enrolled 400 pregnant or lactating women, assuming an α of 0.05, 5% precision, and a conservative estimate of 50% prevalence of vaccine hesitance among pregnant women, given the variability of coverage data on maternal vaccination in Kenya; we allowed for 3% incompletion or non-response and rounded our sample size up slightly for more even distribution between the two counties. We evenly distributed the target sample between the two counties, with facility allocations varying by catchment population and typical facility attendance.Further details on sample size and facilities are described by Limaye et al [23].

Data collectors completed a standard training, which included topics related to the ethical interaction with human participants (role of the data collector, voluntary participation, informed consent, personal privacy, working with vulnerable populations, protection of personal information), data integrity (collection, reporting, and storing data), as well as instrument practice including iterative feedback. The survey instrument was pretested and revised as needed based on language and tone. Scenarios were also provided to data collectors related to these topics to ensure competency of topics and participant interactions.

Recruitment procedures differed by facility; generally, participants were approached consecutively upon arrival at antenatal clinics, maternity wards, or maternal and child health units. If a participant met the inclusion criteria (18 + , currently breastfeeding or in the second or third trimester of pregnancy, and able to consent), oral consent was obtained, with a place on the consent form for the participant to mark an X to indicate their consent. Surveys were administered in either English or Swahili using tablets. Data collection occurred from 25/07/2022 through 21/09/2022. This study received ethical approval from the Kenya Medical Research Institute Scientific and Ethics Review Unit (protocol 4211) in Kenya and Johns Hopkins Bloomberg School of Public Health Institutional Review Board (study IRB00014893) in the US.

The survey instrument included sociodemographic questions, trust in information sources, the importance of a healthcare provider’s recommendation, and concerns about new maternal vaccines. The survey started with questions about RSV risk perception and specific questions about an RSV maternal vaccine, followed by questions about new maternal vaccines broadly. Constructs included in the questionnaire were based on and adapted from relevant theories and models pertaining to vaccine acceptance and behaviors and validated survey tools. These included the SAGE vaccine hesitancy survey tool development guidance, 5C psychological antecedents of vaccination, behavioral and social drivers of vaccination (BeSD) model, socio-ecological model, and health belief model [24–28], as well as the validated Parent Attitudes about Childhood Vaccines (PACV) questionnaire [29–31] and WHO SAGE Vaccine Hesitancy Scale (VHS) [32]. We modified survey items from these tools to focus on maternal vaccination; where appropriate, we separated questions to inquire about mother and newborn separately. The survey instrument was further refined following review and validation during the data collector training.

Trust in information sources.We asked women to indicate their level of trust in a variety of sources, asking participants: “I trust the information that I have received from xx about vaccines during pregnancy.” We asked about the following sources: health care provider, social media platforms, scientists and doctors at universities and academic institutions, and media (TV, radio), and women were given a 4-point Likert scale for answer choices (strongly agree, agree, disagree, strongly disagree).

Healthcare provider recommendation.We asked women to indicate their likelihood of receiving a new vaccine based upon their healthcare provider’s recommendation. We asked: “If a new vaccine was approved for pregnant women, and your health care provider did not recommend it, how likely would you get the new vaccine?” and “If a new vaccine was approved for pregnant women, and your health care provider did recommend it, how likely would you get the new vaccine?”. Women were given a 4-point Likert scale for answer choices (very likely, likely, unlikely, very unlikely).

New vaccine concerns. We asked a question about future vaccine concerns and participants ranked their answers from 1-7 in order of concern, with 1 being most concerning and 7 being least concerning: “When a new vaccine is approved for use and is recommended for me/family, I am typically concerned with the following: a) ingredients in the vaccine; b) side effects; c) availability of the vaccine at my health facility; d) costs to get the vaccine; e) what others are saying about the vaccine; f) healthcare providers recommendation to get the vaccine; and g) a family member, such as a partner or mother-in-law’s input about me getting the vaccine.”

Data analysis

Data were stratified by county and summary statistics of binary and categorical data (including Likert scale data) were calculated for each variable of interest. Categorical demographic data were compared by county using Pearson’s chi-squared test of independence. The level of trust participants had in information sources was summarized and compared by county. Concerns regarding new vaccines and the influence of a health care provider recommendation were summarized by calculating the percent of respondents that chose a concern for each rank.

Results

We surveyed 400 participants, evenly split between Nakuru and Mombasa counties. The majority of participants were between the ages of 18–29, had at least one child, and more than half of participants had a secondary education or higher (Table 1).

Table 1. Sociodemographic characteristics of study sample.

Nakuru (N = 200) Mombasa (N = 200) p-value 1
Age, n(%)
 18-29 132 (66.0) 137 (68.5)
 30-44 68 (34.0) 63 (31.5) 0.594
Lactating, n(%)
 Pregnant 51 (25.5) 50 (25.0)
 Lactating 149 (74.5) 150 (75.0) 0.908
Number of children under 18, n(%)
 None 19 (9.5) 20 (10.0)
 One 63 (31.5) 69 (34.5)
 Two 66 (33.0) 58 (29.0)
 Three 28 (14.0) 36 (18.0)
 Four or more 24 (12.0) 17 (8.5) 0.556
Education level, n(%)
 Less than primary school 15 (7.5) 30 (15.0)
 Primary school completed 68 (34.0) 62 (31.0)
 Secondary/ High school completed 66 (33.0) 55 (27.5)
 College/University completed 51 (25.5) 53 (26.5) 0.097

1 p-values are from Pearson’s Chi-square test of independence

In both Nakuru and Mombasa, 98% of respondents agreed or strongly agreed that they would trust information about new maternal vaccines in pregnancy provided by healthcare providers. A majority of respondents in both counties also trusted information from scientists and/or doctors and media, including TV and radio. Trust in information from social media was low in both counties, as 78% and 80% for Mombasa and Nakuru respectively disagreed that they could trust social media (Fig 1).

Fig 1. Level of trust in information about new maternal vaccines by source.

Fig 1

No respondents chose Strongly Disagree in response to trusting information from healthcare providers. Percentages may not equal 100% due to rounding.

We then asked participants about healthcare provider recommendations. If their healthcare provider recommended a new maternal vaccine, 63% of women in Nakuru and 70% of women in Mombasa indicated that they were very likely to get the new maternal vaccine. If their healthcare provider did not recommend a new maternal vaccine, 5% of women in each county indicated that they were very likely to get the new maternal vaccine (Fig 2).

Fig 2. Influence of healthcare provider recommendations on maternal vaccine acceptance.

Fig 2

Related to concerns about new maternal vaccines, we examined how participants ranked concerns by county of residence and displayed these in a heatmap. The concern that was most frequently ranked as the most important across both counties was vaccine side effects, with the second concern being the vaccine’s ingredients. In both counties, opinions of family members and others were the lowest ranked concerns. (Fig 3).

Fig 3. Concerns about new maternal vaccines ranked.

Fig 3

Values and shades of tiles represent the percent of respondents that chose a particular concern at each rank level. HCP: Healthcare provider.

Discussion

Healthcare providers were highly trusted sources for information about new maternal vaccines among pregnant and lactating women in both Nakuru and Mombasa counties in Kenya. A healthcare provider’s recommendation to receive or not receive a new maternal vaccine holds considerable influence on women as they decide whether to be vaccinated in pregnancy. The main concerns about a new maternal vaccine are the vaccine’s side effects and ingredients. Participants were least concerned about their family’s and others’ opinions about them getting a new maternal vaccine. Responses were similar between the two counties, suggesting negligible difference in opinions between urban and rural populations. While these specific responses were about new maternal vaccines broadly, the questions were prompted by describing maternal RSV vaccines. We believe that this description likely influenced participants to answer questions within the context of maternal RSV vaccines.

While research on maternal RSV vaccines in low- and middle-income countries is lacking, there have been a few studies focused on knowledge and acceptance of RSV vaccines in pregnancy, but these have been conducted in primarily high-income settings. For example, a study among Australian women focused on RSV and Group B Streptococcus (GBS) vaccines in pregnancy found that safety data was the most important factor for acceptance [33]. These findings align with ours as side effects, an important measure for safety, was the biggest concern among women in both counties. For another example, a sample of women in Jordan also found favorable opinions about RSV vaccination during pregnancy, given the vaccine is safe [34]. The concern of vaccine ingredients, which emerged as the second most important in both counties, was not as prevalent in other studies. More research is needed to better understand RSV knowledge and vaccine acceptance among women living in low- and middle-income countries to inform vaccine demand efforts.

Previous research, including from Kenya, has shown that healthcare providers are important and highly trusted sources for health information, including vaccination in pregnancy [35–37]. Aligned with our findings, a recommendation for vaccination from a healthcare provider is central to vaccine acceptance, and the absence of a recommendation can even decrease uptake [35,36]. One study also found that pregnant women even preferred to speak with healthcare providers directly about vaccination, instead of receiving printed communication materials [38]. Similar to our results, two previous studies in Kenya also found that traditional media sources such as TV and radio, were utilized and trusted more than social media sources [39,40]. However, despite the potential presence of misinformation on social media, some studies have found social media and Internet platforms as important sources of health information for mothers [41,42]. This points to the importance of ensuring accurate information is present on social media to increase trust and present correct information to those that are already relying on these platforms. Understanding whom women may go to and seek information related to the maternal RSV vaccine will be crucial to equip trusted messengers with the right information once vaccine demand efforts begin.

The growing evidence base on maternal vaccination acceptance highlights the importance of targeted and tailored communication strategies, particularly those that equip healthcare providers to deliver clear and consistent information to their patients throughout pregnancy. Safety concerns, like side effects or concerns about vaccine ingredients, are commonly identified in similar studies. Strengthening surveillance systems to monitor and evaluate adverse events among pregnant women and newborns is one strategy to improve the information available to providers and program officials to guide recommendations and healthcare provider recommendations [43]. Distinguishing serious AEFI from local vaccine reactions, and understanding how common they are, may also help build trust and mitigate concerns about side effects and ingredients. For example, relatively minor side effects (i.e., pain at the injection site, swelling, etc.) from tetanus vaccination in pregnancy have not deterred vaccine acceptance [44]. Discussing these experiences may help providers assuage patients’ concerns and foster greater acceptance of future maternal vaccines. As safety is the most pressing concern related to a new maternal RSV vaccine, ensuring that the framing, tone, and delivery of communication used to address safety concerns is nuanced and persuasive will be required for successful rollout.

RSV vaccine is recommended in the third trimester, a relatively narrow window compared to other vaccines in pregnancy (i.e., tetanus toxoid) which may be given at any time in pregnancy. A study in Kenya found that two in three pregnant women had their first antenatal care (ANC) visit prior to this window [45]. This may lay the groundwork for healthcare providers to prepare pregnant women for newer maternal vaccines by providing information and addressing concerns during their first ANC visits, before they are eligible to receive these vaccines. For example, Nyawanda et al. noted that healthcare providers in Kenya describe suboptimal RSV disease knowledge but are highly supportive of RSV vaccination for pregnant women [21]. This highlights the importance of strengthening healthcare provider training and knowledge in advance of vaccine availability, including interpersonal communication techniques to engage women early in their pregnancies and support informed RSV vaccine decision-making and follow-up.

Our study found that media is a trusted information source among pregnant and lactating women; this mirrors the findings of a systematic review by De Brabandere and colleagues, which elucidated the importance of the internet and social media in shaping maternal vaccine knowledge and attitudes [41]. Targeted media and social media campaigns in advance of RSV vaccine availability should include messages emphasizing the opportunity for mothers to protect their newborns by being vaccinated themselves, and including information about vaccine safety as well as efficacy. As the RSV vaccine has been primarily rolled out in higher-income countries, studies in Australia and the U.S. have emphasized the effectiveness of media and social media messaging that centers the dual benefits of maternal vaccination for both mother and baby, and the unique agency of mothers to further protect their newborns through maternal vaccination [46,47].

This study had several limitations. First, participants were exclusively recruited from health facilities, so the opinions of women who do not seek care through the formal health system are missed. We sought to recruit a diverse sample of study participants related to age, education, and parity. In addition, social desirability bias may have influenced participants to respond with more favorable views of vaccines or healthcare providers than they actually believed. We adapted established, validated vaccine hesitancy survey tools for our study but note that there may be important differences when inquiring about vaccination in pregnancy; further study to validate this adapted scale would be beneficial. Despite these limitations, the study also had notable strengths. Participants were recruited from both urban and rural settings in different parts of the country. This is also one of the first studies to address information needs for future maternal vaccines, which is crucial for demand generation and community sensitization.

Pregnant and lactating women rely on trusted sources to inform their decision-making related to maternal vaccines. As our study revealed that a strong recommendation from a healthcare provider would likely be the most important influence, it will be imperative to equip healthcare providers with salient and digestible information to be able to strongly recommend a future maternal RSV vaccine. Healthcare providers can also be vaccine hesitant, and efforts to provide relevant information to them well before a maternal RSV vaccine is available is therefore important to realize the potential benefits of a maternal RSV vaccine at the population level.

Supporting information

S1 File. Inclusivity in global research.

(DOCX)

pgph.0004499.s001.docx (65.8KB, docx)

Data Availability

We cannot share data as there is potentially identifying information that could identify participants. All data requests can be sent to either of the following IRB contacts: KEMRI: director@kemri.org JHU IRB: BSPH.irboffice@jhu.edu.

Funding Statement

This study was funded by the Gates Foundation (grant INV-016977) to R.J.L/R.A.K. at the Johns Hopkins Bloomberg School of Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Esposito S, Abu Raya B, Baraldi E, Flanagan K, Martinon Torres F, Tsolia M. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Front Immunol. 2022;13:880368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Geoghegan S, Shuster S, Butler KM, Feemster KA. Understanding Barriers and Facilitators to Maternal Immunization: A Systematic Narrative Synthesis of the Published Literature. Matern Child Health J. 2022;26(11):2198–209. doi: 10.1007/s10995-022-03508-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Quincer EM, Cranmer LM, Kamidani S. Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions. Pathogens. 2024;13(3):200. doi: 10.3390/pathogens13030200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K, et al. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol. 2022;226(4):459–74. doi: 10.1016/j.ajog.2021.10.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Raut S, Apte A, Srinivasan M, Dudeja N, Dayma G, Sinha B, et al. Determinants of maternal influenza vaccination in the context of low- and middle-income countries: A systematic review. PLoS One. 2022;17(1):e0262871. doi: 10.1371/journal.pone.0262871 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Vress D. Future vaccines in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2021;76:96–106. doi: 10.1016/j.bpobgyn.2021.03.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sosa M, Haghighi C, Pike M, Stolarczuk JE, Martinez-King C, Shree R, et al. Perception of a novel group B streptococcus vaccine among pregnant and lactating individuals. The Pediatric Infectious Disease Journal. 2025;44(2S):S149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet. 2022;399(10340):2047–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wang X, Li Y, Shi T, Bont LJ, Chu HY, Zar HJ, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024;403(10433):1241–53. doi: 10.1016/S0140-6736(24)00138-7 [DOI] [PubMed] [Google Scholar]
  • 10.Pecenka C, Sparrow E, Feikin DR, Srikantiah P, Darko DM, Karikari-Boateng E, et al. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children. The Lancet. 2024;404(10458):1157–70. [DOI] [PubMed] [Google Scholar]
  • 11.World Health Organization. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 23-26 September 2024. 2024. https://cdn.who.int/media/docs/default-source/immunization/sage/2024/september/sage-sept_2024-highlights_final.pdf?sfvrsn=6a0f811d_3 [Google Scholar]
  • 12.Terstappen J, Hak SF, Bhan A, Bogaert D, Bont LJ, Buchholz UJ, et al. The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect Dis. 2024;24(12):e747–61. doi: 10.1016/S1473-3099(24)00455-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zar HJ, Piccolis M, Terstappen J, Mazur NI, Gaayeb L, Morin S, et al. Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs-reducing global inequity. Lancet Glob Health. 2024;12(10):e1582–3. doi: 10.1016/S2214-109X(24)00258-4 [DOI] [PubMed] [Google Scholar]
  • 14.World Health Organization. Weekly Epidemiological Record. Weekly Epidemiological Record. 2024;99(49):719–40. https://iris.who.int/handle/10665/379717 [Google Scholar]
  • 15.Nyawanda BO, Murunga N, Otieno NA, Bigogo G, Nyiro JU, Vodicka E, et al. Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010–2018. BMC Med. 2023;21(1):122. Available from: doi: 10.1186/s12916-023-02787-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wambua J, Munywoki PK, Coletti P, Nyawanda BO, Murunga N, Nokes DJ, et al. Drivers of respiratory syncytial virus seasonal epidemics in children under 5 years in Kilifi, coastal Kenya. PLoS One. 2022;17(11):e0278066. doi: 10.1371/journal.pone.0278066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Nyiro JU, Nyawanda BO, Mutunga M, Murunga N, Nokes DJ, Bigogo G, et al. The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya. BMC Public Health. 2024;24(1):2410. doi: 10.1186/s12889-024-19875-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Srikantiah P, Klugman KP. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants. BMC Med. 2023;21(1):177. doi: 10.1186/s12916-023-02883-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Singh P, Fesshaye B, Lee C, Njogu RN, Karron RA, Limaye RJ. Maternal Immunization Decision-Making Among Pregnant and Lactating People in Kenya: A Qualitative Exploration of Peer Influences on Vaccine Decision-Making for a Future RSV Vaccine. Matern Child Health J. 2024;28(10):1822–32. doi: 10.1007/s10995-024-03982-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Limaye RJ, Fesshaye B, Singh P, Karron RA. RSV awareness, risk perception, causes, and terms: Perspectives of pregnant and lactating women in Kenya to inform demand generation efforts for maternal RSV vaccines. Hum Vaccin Immunother. 2023;19(2):2258580. doi: 10.1080/21645515.2023.2258580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nyawanda BO, Opere VA, Nyiro JU, Vodicka E, Fleming JA, Baral R, et al. Respiratory Syncytial Virus (RSV) Disease and Prevention Products: Knowledge, Attitudes, and Preferences of Kenyan Healthcare Workers in Two Counties in 2021. Vaccines (Basel). 2023;11(6):1055. doi: 10.3390/vaccines11061055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gavaruzzi T, Ceccarelli A, Nanni C, Vignali C, Colonnello V, Caserotti M, et al. Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review. Vaccines (Basel). 2025;13(2):159. doi: 10.3390/vaccines13020159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Limaye RJ, Sauer M, Njogu R, Singh P, Fesshaye B, Karron RA. Characterizing attitudes toward maternal RSV vaccines among pregnant and lactating persons in Kenya: key considerations for demand generation efforts for vaccine acceptance. Journal of the Pediatric Infectious Diseases Society. 2023;12(12). [DOI] [PubMed] [Google Scholar]
  • 24.Bronfenbrenner U. The Ecology of Human Development: Experiments by Nature and Design. Harvard University Press. 1979. [Google Scholar]
  • 25.Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. PLoS One. 2018;13(12):e0208601. doi: 10.1371/journal.pone.0208601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E. Measuring vaccine hesitancy: The development of a survey tool. Vaccine. 2015;33(34):4165–75. [DOI] [PubMed] [Google Scholar]
  • 27.Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15(2):175–83. doi: 10.1177/109019818801500203 [DOI] [PubMed] [Google Scholar]
  • 28.Alagarsamy S, Mehrolia S, Pushparaj U, Jeevananda S. Explaining the intention to uptake COVID-19 vaccination using the behavioral and social drivers of vaccination (BeSD) model. Vaccine X. 2022;10:100140. doi: 10.1016/j.jvacx.2021.100140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Opel DJ, Taylor JA, Zhou C, Catz S, Myaing M, Mangione-Smith R. The relationship between parent attitudes about childhood vaccines survey scores and future child immunization status: a validation study. JAMA Pediatrics. 2013;167(11):1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Opel DJ, Taylor JA, Mangione-Smith R, Solomon C, Zhao C, Catz S, et al. Validity and reliability of a survey to identify vaccine-hesitant parents. Vaccine. 2011;29(38):6598–605. doi: 10.1016/j.vaccine.2011.06.115 [DOI] [PubMed] [Google Scholar]
  • 31.Opel DJ, Mangione-Smith R, Taylor JA, Korfiatis C, Wiese C, Catz S, et al. Development of a survey to identify vaccine-hesitant parents: the parent attitudes about childhood vaccines survey. Hum Vaccin. 2011;7(4):419–25. doi: 10.4161/hv.7.4.14120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Larson HJ, Schulz WS, Tucker JD, Smith DMD. Measuring vaccine confidence: introducing a global vaccine confidence index. PLoS Curr. 2015;7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Giles ML, Buttery J, Davey MA, Wallace E. Pregnant women’s knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines. Vaccine. 2019;37(44):6743–9. [DOI] [PubMed] [Google Scholar]
  • 34.Kherfan T, Sallam M. Prospective Attitudes towards Respiratory Syncytial Virus (RSV) Vaccination: Validation of a Survey Instrument among Young Females in Jordan Pending Vaccine Authorization. Vaccines (Basel). 2023;11(8):1386. doi: 10.3390/vaccines11081386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kilich E, Dada S, Francis MR, Tazare J, Chico RM, Paterson P, et al. Factors that influence vaccination decision-making among pregnant women: A systematic review and meta-analysis. PLoS One. 2020;15(7):e0234827. doi: 10.1371/journal.pone.0234827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.MacDougall DM, Halperin SA. Improving rates of maternal immunization: Challenges and opportunities. Hum Vaccin Immunother. 2016;12(4):857–65. doi: 10.1080/21645515.2015.1101524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Nganga SW, Otieno NA, Adero M, Ouma D, Chaves SS, Verani JR, et al. Patient and provider perspectives on how trust influences maternal vaccine acceptance among pregnant women in Kenya. BMC Health Serv Res. 2019;19(1):747. doi: 10.1186/s12913-019-4537-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Maisa A, Milligan S, Quinn A, Boulter D, Johnston J, Treanor C, et al. Vaccination against pertussis and influenza in pregnancy: a qualitative study of barriers and facilitators. Public Health. 2018;162:111–7. doi: 10.1016/j.puhe.2018.05.025 [DOI] [PubMed] [Google Scholar]
  • 39.Fesshaye B, Lee C, Paul AM, Zavala E, Singh P, Karron RA. A qualitative inquiry in understanding trusted media sources to reduce vaccine hesitancy among Kenyans. Frontiers in Communication. 2023;8. [Google Scholar]
  • 40.Shah J, Abeid A, Sharma K, Manji S, Nambafu J, Korom R, et al. Perceptions and Knowledge towards COVID-19 Vaccine Hesitancy among a Subpopulation of Adults in Kenya: An English Survey at Six Healthcare Facilities. Vaccines (Basel). 2022;10(5):705. doi: 10.3390/vaccines10050705 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.De Brabandere L, Hendrickx G, Poels K, Daelemans W, Van Damme P, Maertens K. Influence of the COVID-19 pandemic and social media on the behaviour of pregnant and lactating women towards vaccination: a scoping review. BMJ Open. 2023;13(2):e066367. doi: 10.1136/bmjopen-2022-066367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Moon RY, Mathews A, Oden R, Carlin R. Mothers’ Perceptions of the Internet and Social Media as Sources of Parenting and Health Information: Qualitative Study. J Med Internet Res. 2019;21(7):e14289. doi: 10.2196/14289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kajungu D, Muhoozi M, Stark J, Weibel D, Sturkenboom MCJM. Vaccines safety and maternal knowledge for enhanced maternal immunization acceptability in rural Uganda: A qualitative study approach. PLoS One. 2020;15(12):e0243834. doi: 10.1371/journal.pone.0243834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Johm P, Nkoum N, Ceesay A, Mbaye EH, Larson H, Kampmann B. Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal. Vaccine. 2021;39(29):3926–34. doi: 10.1016/j.vaccine.2021.05.068 [DOI] [PubMed] [Google Scholar]
  • 45.Nyiro JU, Nyawanda BO, Bukusi E, Mureithi MW, Murunga N, Nokes DJ, et al. Assessment of gestational age at antenatal care visits among Kenyan women to inform delivery of a maternal respiratory syncytial virus (RSV) vaccine in low- and middle-income countries. Wellcome Open Res. 2023;8:154. doi: 10.12688/wellcomeopenres.19161.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Marcell L, Dokania E, Navia I, Baxter C, Crary I, Rutz S, et al. One Vax Two Lives: a social media campaign and research program to address COVID-19 vaccine hesitancy in pregnancy. Am J Obstet Gynecol. 2022;227(5):685–695.e2. doi: 10.1016/j.ajog.2022.06.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Carew C, Rak A, Tuckerman J, Pidd D, Vasiliadis S, Danchin M, et al. A qualitative exploration of Australian women’s vaccination experiences and information needs for routine, COVID-19 and respiratory syncytial virus vaccines in pregnancy. Midwifery. 2025;146:104402. doi: 10.1016/j.midw.2025.104402 [DOI] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004499.r002

Decision Letter 0

Claire E von Mollendorf

20 May 2025

PGPH-D-25-00691

Trust in healthcare providers, information sources, and concerns for new maternal vaccines among pregnant and lactating women in Kenya

PLOS Global Public Health

Dear Dr. Limaye,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

EDITOR: 

Ensure that the manuscript conforms to the reporting guidelines for an observational study (STROBE).

==============================

Please submit your revised manuscript by Jul 04 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Claire E. von Mollendorf

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/globalpublichealth/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

2. In the online submission form, you indicated that [Data will be made available upon reasonable request.].

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either

a. In a public repository,

b. Within the manuscript itself, or

c. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?-->?>

Reviewer #1: I don't know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: I appreciate the opportunity to review your study aiming to understand decision-making factors among pregnant and lactating women for receiving a newly licensed vaccine during pregnancy. Below are my comments and suggestions that I believe would enhance the quality and impact of your research.

Major Points

Introduction:

• It is imperative for the authors to cite and discuss more than one prior research study addressing the same research problem. This context will underscore the novelty of your study and help differentiate it from previous attempts.

• Clearly state the aim and objectives of your study at the conclusion of the introduction section to provide a concise overview of your research goals.

Methods:

• The sampling strategy should be clearly defined and reported in the methods section.

• Authors should clarify how the sample size was determined.

• Line 110 “Data collectors completed a standard training, and the survey instrument was pretested.” What does ‘standard’ mean? What did they do in the training and what made you sure they were ready to collect data?

• The authors fail to provide any information in their manuscript that would allow readers to understand how the sample differs from the target population, particularly in terms of key sociodemographic characteristics such as age, gender, and others. This lack of information raises concerns about the representativeness of the sample.

• Authors should clarify how they estimated the reliability or internal consistency of the questionnaire used, using, for example, Cronbach’s alpha to measure whether a score is reliable.

• More information should be provided regarding the considerations concerning the literature review (please add the references) and the authors' previous research experience in developing the questionnaire.

• The study should use additional statistical analysis. Specifically, information on how the authors assessed the normality of numeric variables and any relevant assumptions made for the chosen statistical tests or models should be reported to enhance the transparency and reliability of the statistical analysis. Also, information should be added regarding the logistic regression analysis used (e.g., independent and dependent variables, assumptions, etc.)

• Line 139-140 “New vaccine concerns. We asked question about future vaccine concerns and asked 140 participants to rank their answers from 1-6,…”. Not clear whether the ranking is a score or the number of options, if number of options 7 were actually given.

Results:

• Detailed findings from the statistical analyses used such as the logistic regression models should be reported in the text of the Results section. The authors should create new tables reporting the results from these analyses, which should be included among the main tables of the manuscript.

Discussion:

• The discussion section does well to explore the underlying meaning of the research and its potential implications in other areas of study. The authors have discussed how their findings contribute to the existing knowledge and highlight the significance of their research within a broader context. However, they should consider addressing possible improvements or future directions that can further develop the concerns of their research.

• Lines 195-197 “While these specific responses were about new maternal vaccines broadly, the questions were prompted by describing maternal RSV vaccines.” Critically state if you feel this made any difference.

• Lines 199-208 “While research on maternal RSV vaccines in low- and middle-income countries is lacking, there have been a few studies focused on knowledge and acceptance of RSV vaccines in pregnancy. A study among Australian women focused on RSV and Group B Streptococcus (GBS) vaccines in pregnancy found that safety data was the most important factor for acceptance (17). These findings align with ours as side effects, an important measure for safety, was the biggest concern among women in both counties. A sample of women in Jordan also found favorable opinions about RSV vaccination during pregnancy, given the vaccine is safe (18). The concern of vaccine ingredients, which emerged as the second most important in both counties, was not as prevalent in other studies.”. You begin the paragraph talking about low- and middle-income countries but go on to discuss Australia and Jordan instead.

• Lines 240-251 “RSV vaccine is recommended in the third trimester, a relatively narrow window 241 compared to other vaccines in pregnancy (i.e., tetanus toxoid) which may be given at 242 any time in pregnancy. A study in Kenya found that two in three pregnant women had 243 their first antenatal care (ANC) visit prior to this window (29). This may lay the 12 244 groundwork for healthcare providers to prepare pregnant women for newer maternal 245 vaccines by providing information and addressing concerns during their first ANC visits, 246 before they are eligible to receive these vaccines. Our study found that media is a 247 trusted information source among pregnant and lactating women. Targeted media and 248 social media campaigns in advance of RSV vaccine availability should include 249 messages emphasizing the opportunity for mothers to protect their newborns by being 250 vaccinated themselves, and including information about vaccine safety as well as 251 efficacy (30).” You begin the paragraph talking about uptake of RSV vaccine and then sharply switch to discussion about the media. These should be two separate paragraphs expanded on and discussing other published research.

Reviewer #2: This cross-sectional survey aimed to understand decision-making factors among pregnant and lactating women for receiving a newly licensed vaccine during pregnancy. As far as respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections among infants under six months of age, it is important to conduct cross-sectional survey to understand which information sources pregnant women trusted and their intentions toward future maternal vaccines given in pregnancy, and conducting survey will have an integral role in the working process of determining appropriate measures required to equip healthcare providers with salient and digestible information to be able to strongly recommend a future maternal RSV vaccine, and pregnant and lactating women rely on trusted sources to inform their decision-making related to maternal vaccines.

The manuscript is technically sound, and the data supports the conclusions, and it describes methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented. Furthermore, conclusions are presented in an appropriate fashion and are supported by the data, and the data presented in the manuscript supported the conclusions drawn, and the authors did not overstate their conclusions. The language in the submitted article is clear, correct, and unambiguous and is written in standard English. The research meets all applicable standards for the ethics of experimentation and research integrity. The article adheres to appropriate reporting guidelines and community standards for data availability. Moreover, the manuscript is well organized and written clearly enough to be accessible to non-specialists.

Generally, the article is suitable for publication subject to the following minor corrections or comments for revision and submission to current or other journals. Here below I tried to put my concerns!

Abstract:

Dear author, in the abstract section, you stated that pregnant and lactating women from two counties in Kenya, Nakuru and Mombasa, were recruited to complete a cross-sectional survey in August-September 2022. However, in the methods section, you stated that data collection occurred from 25/07/2022 through 21/09/2022. It is recommended that the author should report consistently.

Another concern in the abstract section: it is better to include an adjusted odds ratio (AOR) with a 95% confidence interval (CI) which was used to measure the strength of the association between factors and the outcome variable. In addition, it is better to include the statistical software used for data entry and analysis and the sampling methods used to recruit pregnant and lactating women from two counties in Kenya, Nakuru and Mombasa, to complete a cross-sectional survey.

Methods:

Dear author, You stated that participants were recruited from 20 health facilities in Nakuru County (rural) and Mombasa County (urban). A range of health facility types was included, from level 2 through level 5 (line numbers 107-109). However, you did not provide in detail the sampling technique and procedure employed to arrive at the desired sample size (400 pregnant and lactating women).

Furthermore, it is recommended to provide the sample size determination, data processing and analysis used in this study.

Results:

Dear author, You reported that nearly half of participants had at least a secondary education (line number 150). However, Table 1 showed that the percentages of participants who completed a secondary education in Nakuru and Mombasa counties were 33% and 27.5%, respectively. It is better to revise it.

Regarding trust in information from traditional media, 31% disagreed and 68% agreed for Nakuru participants (Figure 1). The summation of participants who disagreed and agreed was 99%. Dear author, the summation of participants should be 100%. It is recommended that the author should revise Figure 1.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004499.r004

Decision Letter 1

Claire E von Mollendorf

20 Oct 2025

Trust in healthcare providers, information sources, and concerns for new maternal vaccines among pregnant and lactating women in Kenya

PGPH-D-25-00691R1

Dear Dr. Limaye,

We are pleased to inform you that your manuscript 'Trust in healthcare providers, information sources, and concerns for new maternal vaccines among pregnant and lactating women in Kenya' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Claire E. von Mollendorf

Academic Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Comments to the Author

Reviewer #2: All comments have been addressed

**********

publication criteria?>

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?-->?>

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??>

The PLOS Data policy

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #2: Yes

**********

Reviewer #2: Dear Authors,

Thank you for your diligent efforts in addressing the peer-review comments. Your revisions have significantly enhanced the manuscript’s clarity and quality. The dates in the methods section have been corrected to align with those in the abstract. You have also provided additional details on sample size determination, sampling strategy, and data analysis as recommended.

Moreover, the results section now clearly indicates that over half of the participants had secondary education or higher, encompassing both secondary and college-level education. Your thorough responses to the peer-review report and adherence to the manuscript revision criteria are appreciated. Each point has been carefully considered and necessary adjustments have been made to improve the overall quality and clarity of the manuscript.

However, it would be beneficial to include a limitations section at line 329 and ensure the conclusion section starts at line 343. Please ensure these sections are added.

Overall, the article is suitable for publication.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #2: Yes:  Gemechu Dereje Feyissa

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Inclusivity in global research.

    (DOCX)

    pgph.0004499.s001.docx (65.8KB, docx)
    Attachment

    Submitted filename: PLOS GH Response to Reviewer Comments.docx

    pgph.0004499.s003.docx (20.1KB, docx)

    Data Availability Statement

    We cannot share data as there is potentially identifying information that could identify participants. All data requests can be sent to either of the following IRB contacts: KEMRI: director@kemri.org JHU IRB: BSPH.irboffice@jhu.edu.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES